Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
- 6 October 2021
- journal article
- review article
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 37 (12) , 581-589
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Symptom Severity Influences Drug Efficacy in Women with Diabetic Gastroparesis: Results of a Phase 3 Study with Metoclopramide Nasal SprayGastroenterology, 2017
- Mo1607 Supratherapeutic Dose of Metoclopramide Nasal Spray Shown to Have No ECG Effects in Healthy Male and Female Volunteers: Results of the First Metoclopramide Thorough ECG StudyGastroenterology, 2016
- Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized StudyClinical Gastroenterology and Hepatology, 2015
- 71 Metoclopramide Nasal Spray Provides Symptom Relief in Women With Diabetic Gastroparesis: Results of a Phase 2B Study.Gastroenterology, 2014
- Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tabletNeurogastroenterology & Motility, 2013
- The relationship between gastric motility and nausea: Gastric prokinetic agents as treatmentsEuropean Journal of Pharmacology, 2013
- Clinical Guideline: Management of GastroparesisAmerican Journal of Gastroenterology, 2013
- Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptomsQuality of Life Research, 2004
- Comparison of The Pharmacokinetics and Safety of Metoclopramide, Nasal Spray Versus Orally Administered Metoclopramide Tablets, USP in Patients With Diabetic GastroparesisClinical Pharmacology & Therapeutics, 2003
- The Gastroprokinetic and Antiemetic Drug Metoclopramide Is a Substrate and Inhibitor of Cytochrome P450 2D6Drug Metabolism and Disposition, 2002